Differences between the teriparatide (TPTD) and alendronate (ALN) treatment groups in the mean percentage increase in bone mineral density (BMD) from baseline to 18 months.
| Lumbar Spine BMD | Femoral Neck BMD | Total Hip BMD | ||||
|---|---|---|---|---|---|---|
| Difference TPTD vs ALN, % | p | Difference TPTD vs ALN, % | p | Difference TPTD vs ALN, % | p | |
| Baseline glucocorticoid dose, mg/day | ||||||
| Overall | 3.6 | < 0.001 | 1.2 | 0.100 | 0.9 | 0.069 |
| Low (≤ 5 mg/day) | 4.5 | < 0.001 | 1.9 | 0.073 | 1.3 | 0.086 |
| Medium (> 5 and < 15 mg/day) | 3.9 | < 0.001 | 2.0 | 0.039 | 1.6 | 0.022 |
| High (≥ 15 mg/day) | 2.3 | 0.150 | −0.3 | 0.857 | −0.03 | 0.977 |
| Interaction* | p = 0.52 | — | p = 0.46 | — | p = 0.49 | — |
↵* Between 2 treatment groups and across 3 glucocorticoid dose categories.